Interested in speaking? Apply Here!

Agenda

MAIN CONFERENCE DAY ONE | Tuesday, April 30, 2019
7:45AM
Registration and Morning Coffee
8:30AM
CO-CHAIRS' OPENING KEYNOTE
Strategic Vision: A Global Strategic Vision for Digital Health in Pharma
  • Digital health has been a massive movement throughout all corners of the global healthcare ecosystem, yet life science organizations are just now getting serious about the opportunities
  • This conference offers the first-ever focused opportunity for life science leaders to convene and discuss these possibilities across the value chain and their organizations, and hopefully drive our industry forward
  • An overview of the value models for digital health in the life sciences, and how life science organizations can think about how to (eventually) drive commercial value from digital health initiatives
    • "Invest"
    • "Incubate/Accelerate"
    • "Commercialize"
    • "Collaborate"
    • "Co-Develop"
Paul Ivans, Founder and CEO, EVOLUTION ROAD
Larry Brooks, Principal, Digital Health Practice Leader, EVOLUTION ROAD
9:00AM
PHARMA KEYNOTE
Strategic Vision for Digital Health in Pharma - The Global/U.S. Perspective
Shwen Gwee, General Manager, Digital Accelerator, Global Drug Development, NOVARTIS, USA
9:30AM
PHARMA KEYNOTE
Digital Health: How to Unlock Value in Times of Pharma Disruption

We all know that the script is flipping in Pharma – disruption is coming – it’s just a matter of how soon. So how can we accelerate in this time of change and unlock value? Hear how GSK is doubling down on Customer Obsession and driving a culture change fueled by data. You will hear how innovation projects are accelerating and GSK is finding more modern ways to measure impact. You will also gain some practical tips to help jumpstart your disruption journey.

Angela Horstmann, Head of Consumer Digital Experience and Innovation, U.S. PharmaCustomer Capabilities and Operations, GLAXOSMITHKLINE
Andy Kennemer, Vice President, Digital Customer Experience and Innovation, GLAXOSMITHKLINE
Barbara Salami, Head, Customer Experience Optimization, GLAXOSMITHKLINE
10:00AM
PHARMA KEYNOTE
Digital Health: Insider Perspectives and Lessons Learned
  • Lessons learned from leading digital transformation in pharma on a global scale
  • Perspectives from advising digital health and tech companies
  • Keys to success, resilience, and watch-outs along the way
Nancy Phelan, Chief Business Officer, INNATE BIOLOGICS
10:30AM
Morning Networking Break
11:00AM
Panel Discussion

Digital Therapeutics: Understanding this growing area within digital health, and learning how life science organizations can effectively collaborate and partner to help solve unmet customer needs?

Learn about the rapidly evolving and growing area of digital therapeutics and how these “hot companies” are viewing the life science industry, and how they are partnering with your peers and competitors today.

Moderator:

Megan Coder, Executive Director, DIGITAL THERAPEUTICS ALLIANCE

Panelists:

Bryan Mallitz, Director, Digital Health Strategy and Solutions, MERCK VACCINES
Eddie Martucci, Ph.D., CEO and Co-Founder, AKILI INTERACTIVE
Joel Sangerman, Chief Commercial Officer, CLICK THERAPEUTICS, INC.
Joe Slavinsky, Vice President, Business Development, PROPELLER HEALTH
Ryan Sysko, CEO, AMALGAM RX, INC.

11:30AM
Panel Discussion "INVEST"
Digital Health Investor Panel - A View From the Other Side - Pharma Investors, Private Equity/Venture Capital
Panelists:

Gary Kurtzman, Managing Diector, Healthcare, SAFEGUARD SCIENTIFICS
Sasha Said, Vice President, Digital Health investor, LEERINK TRANSFORMATION PARTNERS

12:00PM
PHARMA KEYNOTE
5 Years of Learnings and What’s Next — Leveraging Digital Health Solutions to Address Key Unmet Needs in GI

MY GI Health is an automated patient assessment that was developed as a remote, online and in-office application to improve patient-physician communication by evaluating all key gastrointestinal symptoms across multiple GI disorders, instantaneously creating a patient history, and providing patient education videos and treatment information. Over the past few years, this tool has reached far beyond the original concept of efficiently and comprehensively extracting and summarizing patient information to aid physicians in caring for patients. Through its application the app has improved the quality of patient histories captured in EHRs, large scale surveys better-characterized patient needs, revealed extensive comorbid GI disorders and better quantified patient epidemiology and burden of illness. These data have been leveraged to quantify commercial opportunities, guide clinical trial design and recruitment and inform brand strategy and investments. This experience has spurred a broader interest to explore the opportunity to improve identification and understanding of rare GI diseases, reduce the time and cost of clinical trials and link to communication networks to document and improve quality of care.

Thomas McCourt, Chief Commercial Officer and Senior Vice President, Marketing and Sales, IRONWOOD PHARMACEUTICALS
12:30PM
PHARMA KEYNOTE
The Hammer of Disruption: Surviving, Thriving, and Staying Alive in a Mid-Disruption Ecosystem

It's not (just) the tech: why partnering and business models enable the future of patient care

  • Identifying new products and services relevant to neurology patients
  • Cultivating partnerships and pursuing strategic opportunities with mission-driven companies
  • Designing new business models orientated toward increased value delivery to health systems, improved patient experience and outcomes
James Musick, Vice President, Head of Neurology Patient Technology U.S., UCB PHARMACEUTICALS
1:00PM
Networking Luncheon
2:00PM
PHARMA KEYNOTE
Thinking Differently to Take Advantage of Digital Health Innovation Techniques In-House and Agility Measures
Nicole Mowad-Nassar, Vice President, Commercial Analytics and Operations, ABBVIE
2:30PM
PHARMA KEYNOTE
“COMMERCIALIZE”
Rachel Sha, Vice President, Digital Business Development, SANOFI
3:00PM
PHARMA KEYNOTE SESSION
Digital Health and the Importance of Embedding Data and Technology-Driven Decision-Making Into Company Culture

Pharma started to innovate and partner to bring in data, tools, and technology, but many are still looking for how to be successful with these new endeavors. One key aspect is that the people in an organization need to be prepared to utilize it and put these new tools against real business cases. In this session, we will explore five key questions that organizations should ask before diving into digital health and explore how to embed data and tech-driven decision making into the company culture.

Miruna Sasu, Head of Innovation and Digital Health, BRISTOL-MYERS SQUIBB
3:30PM
Panel Discussion PHARMA DIGITAL HEALTH THOUGHT LEADERS KEYNOTE: Pulling Perspectives Together
  1. Invest
  2. Incubate/Accelerate
  3. Commercialize
  4. Collaborate
  5. Co-Develop
Moderator:

Larry Brooks, Principal, Digital Health Practice Leader, EVOLUTION ROAD

Panelists:

Bryan Mallitz, Director, Digital Health Strategy and Solutions, MERCK VACCINES
James Musick, Vice President, Head of Neurology Patient Technology U.S., UCB PHARMACEUTICALS
Amy West, Senior Director, Patient Marketing and Digital Health Innovation, NOVO NORDISK

4:00PM
Afternoon Networking and Refreshment Break
MAIN CONFERENCE DAY ONE TRACKED SESSIONS | Tuesday, April 30, 2019
TRACK A
Digital Health + Patient Engagement Intersect

TRACK B
Digital Health Case Studies in the Real World

4:40PM
Track Chair's Opening Remarks
Track Chair's Opening Remarks
4:45PM
CASE STUDY
Digital Connectivity and Its Role in Disease Management and Patient Engagement
  • Examining the role digital connectivity has in patient disease management and support beyond adherence
  • Understanding and balance technical complexity and simplicity to create a unique and positive user experience
  • Polymedicine challenges and consideration — short-term approach and long-term considerations
  • Exploring opportunities for pharma, patient and HCP engagement through digital support ecosystem
Michael C. Song, Ph.D., Senior Manager R&D, Device Functionality, Safety, and Digital Connectivity, Drug Delivery and Device Development, BioPharmaceutical Development, MEDIMMUNE
CASE STUDY EUCRISA and Instagram-Branded Page Experience
  • Challenge: Reach eczema sufferers where they are to deliver meaningful value through content and community
  • Strategy: expand the branded social presence of EUCRISA into Instagram, the fastest growing social platform with 21M unique users to Facebook
  • Execution: Brand team partnered with IG, Pfizer Media and the Pfizer Digital Review Team to:
    • Develop unique content to fully harness the visual and inspirational nature of the Instagram platform
    • Foster and facilitate a transparent, meaningful community conversation
  • Results: Launched Pfizer’s first branded Instagram page that allows comments, encourages community interaction and provides “social care” for EUCRISA patients and caregivers consistent with the IG platform while remaining compliant with Pfizer and Government regulatory policies
Alexandra McMenomy, Director, Patient Marketing, PFIZER, INC.
Jennifer Travers, Head, Digital Review Team, PFIZER, INC.
5:15PM
Panel Discussion Patient Influencers Weigh In on Digital Health Adoption

Abstract:

For all its promise, consumer digital health adoption remains a daunting challenge for most pharma companies. There are few if any magic bullets, but plenty of lessons to be learned from patient influencers who understand the adoption challenge as well as anyone. In fact, trusted patient thought leaders are one of the most overlooked allies pharma companies have when it comes to building and marketing new solutions to the broader patient community. Hear from patients with hands-on experience in digital health – what works, what doesn’t and how to innovate with patients, not just for them.

Moderator:

Jack Barrette, CEO, WEGO HEALTH

Panelists:

Kristen Winters, Integrated Multichannel Marketing and Sales Lead, US Market, BAYER

CASE STUDY
Digital Biomarkers in Clinical Trials - Learnings and Prospects

Digital devices such as activity monitors enable the collection of continuous real-world data that provide valuable new insights into the impact of diseases and treatments on patients’ everyday lives. As the implementation of such devices in clinical trials increases, reflecting on case studies and the lessons learned will allow us to overcome the challenges and embrace the opportunities.

Jonas Dorn, Digital Solutions Director, NOVARTIS
5:45PM
CASE STUDY
The Who, What, When, Where and How of Digital Health
To many Pharma companies, Digital Health brings to mind initiatives focusing on what innovations we can deliver and how they can benefit our patients. However, who these patients are and when they are interacting with Pharma brands can sometimes receive less attention. Nevertheless, these considerations are vitally important to creating solutions that provide lasting value. In this session, we’ll explore ways to develop digital health initiatives that fully integrate all customers’ needs
Fred Bennett, Head, Patient Strategy and Engagement, INTERCEPT PHARMACEUTICALS
CASE STUDY
Digitally Detecting Developing Diseases – Computational Intelligence Synergistically Applied to Medical Data and LIFEdata
  • Hear how BioTrillion is developing a health technology platform called BioEngine4D, by applying machine learning and AI to aggregated Medical data and unique LIFEdata — now generatable via the ubiquity of multi-modality sensors existing within key Consumer smart devices
  • Learn how novel digital biomarkers can be developed by computationally training and statistically mapping key diseases, via pathophysiologic-known pathways, to digitally measurable expressions
  • Explore how BioEngine4D can yield entirely new opportunities — to augment existing molecular biomarkers, early detect, and develop novel therapeutics — for a broad array of diseases, such as Alzheimer’s, Parkinson’s, Lung Cancer, and Melanoma
  • Consider how novel uses of multimodal sensors within common smartphones and smartwatches can effectively:
    • Place “a digital doctor” in your Life setting to continuously check for key disease indicators and catalyze earlier clinical diagnoses and timelier intervention
    • Place “clinical trials in a pocket” and disrupt the slow and costly pharma drug development paradigm
Savan Devani, Founder and CEO, BIOTRILLION
6:15PM
Conclusion of Day One and Networking Cocktail Reception
MAIN CONFERENCE DAY TWO | Wednesday, May 1, 2019
8:15AM
Registration Opens and Morning Coffee
8:40AM
Co-Chairs' Opening Remarks for Day Two
Larry Brooks, Principal, Digital Health Practice Leader, EVOLUTION ROAD
Paul Ivans, Founder and CEO, EVOLUTION ROAD
9:00AM
PHARMA KEYNOTE
Incorporating Behavioral Science in Your Next Digital Innovation
Daniel Seewald, Worldwide Head of Innovation, PFIZER, INC.
9:30AM
PHARMA KEYNOTE
Everything Old Is New Again

Pete Dannenfelser, a 20-year veteran of Digital in Pharma Marketing Communications shares lessons and insights from what can be learned and applied from fighting the good fight for digital in its many forms over the years. Today, building excitement, interest, and budget support for digital health are eerily similar to the world of digital marketing in pharma 10–15 years ago.

Pete Dannenfelser, Associate Vice President Communications and Digital Innovation, FERRING PHARMACEUTICALS
10:00AM
PHARMA KEYNOTE 'CO-DEVELOP'
Faster, Smarter, Bigger: Better Together
  • Digital trends from Google’s perspective
  • The power of partnerships: The “Why,” “What,” and “How” answered
Stefani Klaskow, Head of Industry, Healthcare, GOOGLE
Melissa Saw, Global Head, Digital Partnerships, BAYER
10:30AM
Panel Discussion "INCUBATE" Accelerators, Incubators, Innovators, Oh My!
Moderator:

Brian Stevens, Principal, Engagement Manager, EVOLUTION ROAD

Panelists:

Fabio Gratton, Founder and Chief Alchemist, ALCHEMY FACTORY
Shwen Gwee, General Manager, Digital Accelerator, Global Drug Development, NOVARTIS, USA
Bari Krein, J.D., LLM, Chief Strategy Officer, STARTUP HEALTH
Unity Stoakes, Co-Founder, STARTUP HEALTH
David Weingard, CEO, CECELIA HEALTH

11:00AM
Morning Networking Break
11:30AM
PHARMA KEYNOTE
Session Title to Be Determined
Aman Bhatti, Global CHC Medical Head, Digital Health and Medicines, SANOFI
12:00PM
FIRESIDE CHAT
Leveraging Digital Health to Bridge the Gap From R&D to Commercial

Pharma has historically been a siloed industry with thick walls between its R&D and Commercial functions. Digital Health is proving to be an opportunity that has the power to break down the walls and collapse those siloes. Digital Health technologies such as Digital Therapeutics require a collaborative effort across R&D and Commercial, to define the market opportunities, determine the optimal business model for the digital therapeutic as a standalone product or complement to pharmacotherapy, and then to optimize its value proposition to payers, providers, and patients. Melinda and Mo are highly experienced digital health thought leaders with experience across the value chain. Hear their perspectives and vision for how digital health collaborations are best approached for optimal value across life sciences.

Mohammed Ali, Global Head Digital Trials- Global Clinical Operations, BOEHRINGER INGELHEIM
Melinda Decker, Former Head of Oncology and Immuno-Oncology, Digital Therapeutics and Digital Health, FORMERLY ASTRAZENECA
12:30PM
Panel Discussion "LEVERAGE"
Making Digital Health Work in Life Sciences — Lessons Learned From Digital Health Leaders Who Are Running Successful Programs in the Market Today
Moderator:

Lea DeOlivera, Principal, Consulting Practice Leader, EVOLUTION ROAD

Panelists:

Amanda Goltz, Vice President, Digital, BIOCOMPATIBLES INC., A BTG INTERNATIONAL GROUP COMPANY
Michael Latauska, Director, Digital Health, BOEHRINGER INGELHEIM
Dhiren Patel, Pharm.D., Vice President of Medical Affairs, PACKHEALTH
Brent Rose, Executive Director, Consumer/Patient Marketing I&I, CELGENE

1:00PM
Pharma Keynote So You Want to Make Money From Digital Health?

How are life science organizations evolving their business models and making money off of digital? This session will take a detailed overview of the various different business models currently in practice in the market as well as a preview of what is working at LifeScan.

David DeJonghe, Senior Director, Head of Portfolio Strategy, LIFESCAN
1:30PM
TECHNOLOGY DISRUPTORS SHOWCASE
Juanjo Francesch, Vice President, Commercial IT, BRISTOL-MYERS SQUIBB
2:00PM
Networking Luncheon
3:00PM
Panel Discussion Payer Perspectives on Digital Health: How Payers View Digital Health and Pharma's Role in Digital Health
Moderator:

Melissa Thomas, Director, Business Innovation - Digital Health, BOEHRINGER INGELHEIM

Panelists:

Roberto Roitz, Director of Strategic Partnerships, Digital Health and Analytics, HUMANA
Christina Weir, Vice President, Enterprise Clinical Operations, HIGHMARK HEALTH

3:30PM
REGULATORY CASE STUDY
Integrating Patient Feedback Into the Drug and Digital Therapeutics Development Process

Profiling the work of the NIH with the FDA and Patient Advocacy Groups to identify additional clinical endpoints for SaMD approval process

4:00PM
Closing Remarks and Close of Conference

Download the Conference Brochure

Get all of the latest information for this event! Download Now
live chat software